Michael DeCuypere

Dr. Michael DeCuypere

Ann and Robert H. Lurie Children's Hospital, Division of Pediatric Neurosurgery, Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2022 in CNS Oncology
Verified
Journal Article
Open access
JGJohn F. de Groot
John F. de Groot
MOMartina Ott
Martina Ott
JWJun Wei
Jun Wei
CKCynthia Kassab
Cynthia Kassab
DFDexing Fang
Dexing Fang
Amy B. HeimbergerAmy B. Heimberger
Amy B. Heimberger
Aim: To ascertain the maximum tolerated dose (MTD)/maximum feasible dose (MFD) of WP1066 and p-STAT3 target engagement within recurrent glioblastoma (GBM) patients. Patients & methods: In a first-i... Graphical abstract

1 January 2022 in World Neurosurgery
Verified
Journal Article
Closed access
JHJonathan Huang
Jonathan Huang
NSNathan A. Shlobin
Nathan A. Shlobin
SLSandi K. Lam
Sandi K. Lam
MDMichael DeCuypere
Michael DeCuypere

16 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KAKaitlyn Alleman
Kaitlyn Alleman
EKErik Knecht
Erik Knecht
JHJonathan Huang
Jonathan Huang
LZLu Zhang
Lu Zhang
SLSandi Lam
Sandi Lam
MDMichael DeCuypere
Michael DeCuypere
Malignant brain tumors pose a substantial burden on morbidity and mortality. As clinical data collection improves, along with the capacity to analyze it, novel predictive clinical tools may improve prognosis prediction. Deep learning (DL) holds promise for integrating clinical data of various modalities. A systematic review of the DL-based prognostication of gliomas was performed using the Embase (Elsevier), PubMed MEDLINE (National library of Medicine), and Scopus (Elsevier) databases, in accordance with PRISMA guidelines. All included studies focused on the prognostication of gliomas, and predicted overall survival (13 studies, 81%), overall survival as well as genotype (2 studies, 12.5%), and response to immunotherapy (1 study, 6.2%). Multimodal analyses were varied, with 6 studies (37.5%) combining MRI with clinical data; 6 studies (37.5%) integrating MRI with histologic, clinical, and biomarker data; 3 studies (18.8%) combining MRI with genomic data; and 1 study (6.2%) combining histologic imaging with clinical data. Studies that compared multimodal models to unimodal-only models demonstrated improved predictive performance. The risk of bias was mixed, most commonly due to inconsistent methodological reporting. Overall, the use of multimodal data in DL assessments of gliomas leads to a more accurate overall survival prediction. However, due to data limitations and a lack of transparency in model and code reporting, the full extent of multimodal DL as a resource for brain tumor patients has not yet been realized.

13 August 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
STShashwat Tripathi
Shashwat Tripathi
HNHINDA NAJEM
HINDA NAJEM
CDCorey Dussold
Corey Dussold
SPSebastian Pacheco
Sebastian Pacheco
RDRuochen Du
Ruochen Du
MDMichael DeCuypere
Michael DeCuypere
Despite being the leading cause of cancer-related childhood mortality, pediatric gliomas have been relatively understudied, and the repurposing of immunotherapies has not been successful. Whole-transcriptome sequencing, single-cell sequencing, and sequential multiplex immunofluorescence were used to identify an immunotherapeutic strategy that could be applied to multiple preclinical glioma models. MAPK-driven pediatric gliomas have a higher IFN signature relative to other molecular subgroups. Single-cell sequencing identified an activated and cytotoxic microglia (MG) population designated MG-Act in BRAF-fused, MAPK-activated pilocytic astrocytoma (PA), but not in high-grade gliomas or normal brain. T cell immunoglobulin and mucin domain 3 (TIM3) was expressed on MG-Act and on the myeloid cells lining the tumor vasculature but not normal brain vasculature. TIM3 expression became upregulated on immune cells in the PA microenvironment, and anti-TIM3 reprogrammed ex vivo immune cells from human PAs to a proinflammatory cytotoxic phenotype. In a genetically engineered murine model of MAPK-driven, low-grade gliomas, anti-TIM3 treatment increased median survival over IgG- and anti–PD-1–treated mice. Single-cell RNA-Seq data during the therapeutic window of anti-TIM3 revealed enrichment of the MG-Act population. The therapeutic activity of anti-TIM3 was abrogated in mice on the CX3CR1 MG–KO background. These data support the use of anti-TIM3 in clinical trials of pediatric low-grade, MAPK-driven gliomas.

19 December 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
STShashwat Tripathi
Shashwat Tripathi
HNHINDA NAJEM
HINDA NAJEM
CDCorey Dussold
Corey Dussold
SPSebastian Pacheco
Sebastian Pacheco
JMJason Michael Miska
Jason Michael Miska
Amy B. HeimbergerAmy B. Heimberger
Amy B. Heimberger
A recently published JCI paper revealed that cancer-associated fibroblasts (CAFs) are present in glioblastoma and are defined by the presence of 9 transcriptional markers (1). CAFs can form a barrier around cancer cells that prevents their detection by T cells (2). The normal brain has low levels of collagen, but deposition increases in gliomas, especially around vessels. In addition to collagen facilitating tumor invasion and providing a niche for cancer stem cells, collagen has also been shown to trigger immune suppression through LAIR1-mediated T cell exhaustion and alternative activation of macrophages (3, 4). CAFs were identified from single cells isolated from 21 samples (high-grade gliomas [HGGs], 5; pilocytic astrocytomas [PAs], 13; and normal brains [NBs], 3) by examining differential expressed genes against known CAF markers and CAF subtype markers (Figure 1A). The percentage of CAFs was a function of glioma grade, with 1% CAFs present in NBs/low-grade gliomas and nearly 20% in HGGs with an enrichment of the immunomodulatory CAF subtype (Figure 1, B and C). Gene ontology analysis suggested CAF-mediated immune suppression and migration inhibition (Figure 1D). To ascertain the collagen types produced by CAFs, scRNA-Seq data from our pediatric glioma cohort complemented with public adult glioblastoma data sets (5) were analyzed and showed that CAFs expressed COL6A1/A2 > COL4A1, COL9A3, COL12A1 > COL1A (Figure 1E and Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/ JCI176613DS1). ELISA confirmed collagen production by human glioblastoma CAFs at 773 μg/mL. Within the public data set (5), the CAF populations are included in the pericyte compartment. Pericytes expressed the greatest diversity of collagen subtypes and were the main source of COL1A1/A2, COL3A1, COL4A1/A2, COL5A1/A2, COL6A1/A2/A3, and COL18A1; endothelial cells were also a source of COL4A1/A2 and COL18A1. Glioma cells expressed modest levels of COL6A1 and COL9A3 (Supplemental Figure 1A). Prognostic analysis of collagen subtypes from The Cancer Genome Atlas revealed that 6 types were negatively associated with outcome, including COL1A2 (high vs. low expression, 12.3 vs. 16.1 months; HR = 0.68; P = 0.03); COL6A1 (11.9 vs. 15.9 months; HR = 0.53; P = <0.01); COL8A2 (12.6 vs. 15 months; HR = 0.65; P = 0.02); COL22A1 (11.8 vs. 15.4 months; HR = 0.67; P = 0.03); COL24A1 (11.8 vs. 15 months; HR = 0.64; P = 0.01); and COL27A1 (11.8 vs. 15.8 months; HR = 0.63; P = 0.01) (Supplemental Figure 1B). Among the most frequently expressed and prognostic collagens, COL1A2, COL4A1, and COL6A1 were enriched near the hyperplastic vessels and microvascular proliferation, whereas COL1A2 and COL4A1 were enriched in the perinecrotic regions (Supplemental Figure 1C). To validate these findings, multiplex imaging demonstrated that CAFs were embedded in COL6A1/A2 within HGGs (Figure 1F and Supplemental Video 1). COL1A and COL4A were expressed in tumor glomeruloid struc

1 December 2023 in Journal of neurosurgery. Pediatrics
Verified
Journal Article
Closed access
PDF file
MDMahalia Dalmage
Mahalia Dalmage
MLMelissa A. LoPresti
Melissa A. LoPresti
PSProttusha Sarkar
Prottusha Sarkar
SRSruthi Ranganathan
Sruthi Ranganathan
SASunny Abdelmageed
Sunny Abdelmageed
MDMichael DeCuypere
Michael DeCuypere
OBJECTIVE: Diffuse intrinsic pontine gliomas (DIPGs) are aggressive and malignant tumors of the brainstem. Stereotactic biopsy can obtain molecular and genetic information for diagnostic and potentially therapeutic purposes. However, there is no consensus on the safety of biopsy or effect on survival. The authors aimed to characterize neurological risk associated with and the effect of stereotactic biopsy on survival among patients with DIPGs. METHODS: A systematic review was performed in accordance with PRISMA guidelines to identify all studies examining pediatric patients with DIPG who underwent stereotactic biopsy. The search strategy was deployed in PubMed, Embase, and Scopus. The quality of studies was assessed using the Grading of Recommendations, Assessment, Development and Evaluation system, and risk of bias was evaluated with the Cochrane Risk of Bias in Nonrandomized Studies–of Interventions tool. Bibliographic, demographic, clinical, and outcome data were extracted from studies meeting inclusion criteria. RESULTS: Of 2634 resultant articles, 13 were included, representing 192 patients undergoing biopsy. The weighted mean age at diagnosis was 7.5 years (range 0.5–17 years). There was an overall neurosurgical complication rate of 13.02% (25/192). The most common neurosurgical complication was cranial nerve palsy (4.2%, 8/192), of which cranial nerve VII was the most common (37.5%, 3/8). The second most common complication was perioperative hemorrhage (3.6%, 7/192), followed by hemiparesis (2.1%, 4/192), speech disorders (1.6%, 3/192) such as dysarthria and dysphasia, and movement disorders (1.0%, 2/192). Hydrocephalus was less commonly reported (0.5%, 1/192), and there were no complications relating to wound infection/dehiscence (0%, 0/192) or CSF leak (0%, 0/192). No mortality was specifically attributed to biopsy. Diagnostic yield of biopsy revealed a weighted mean of 97.4% (range 91%–100%). Of the studies reporting survival data, 37.6% (32/85) of patients died within the study follow-up period (range 2 weeks–48 months). The mean overall survival in patients undergoing biopsy was 9.73 months (SD 0.68, median 10 months, range 6–13 months). CONCLUSIONS: Children with DIPGs undergoing biopsy have mild to moderate rates of neurosurgical complications and no excessive morbidity. With reasonably acceptable surgical risk and high diagnostic yield, stereotactic biopsy of DIPGs can allow for characterization of patient-specific molecular and genetic features that may influence prognosis and the development of future therapeutic strategies.